Pharsight

Drugs that contain Edaravone

1. Radicava patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6933310 MITSUBISHI TANABE Therapeutic agent for amyotrophic lateral sclerosis (ALS)
Nov, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-144) May 05, 2024
ODE*(ODE*) May 05, 2024
New Chemical Entity Exclusivity(NCE) May 05, 2022
Orphan Drug Exclusivity(ODE) May 05, 2024

NCE-1 date: 05 May, 2021

Market Authorisation Date: 05 May, 2017

Treatment: Treatment of amyotrophic lateral sclerosis (als)

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

RADICAVA family patents

Family Patents

2. Radicava Ors patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478450 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

US10987341 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

US11241416 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

US11826352 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-144) May 12, 2029
New Product(NP) May 12, 2025

Market Authorisation Date: 12 May, 2022

Treatment: Treatment of amyotrophic lateral sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of RADICAVA ORS before it's drug patent expiration?
More Information on Dosage

RADICAVA ORS family patents

Family Patents